Christopher P. Leamon Sells 23,231 Shares of Endocyte, Inc. (NASDAQ:ECYT) Stock

Endocyte, Inc. (NASDAQ:ECYT) VP Christopher P. Leamon sold 23,231 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $5.04, for a total transaction of $117,084.24. Following the sale, the vice president now directly owns 150,579 shares of the company’s stock, valued at approximately $758,918.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Endocyte, Inc. (ECYT) traded up $0.14 during trading on Wednesday, reaching $4.70. 259,145 shares of the company’s stock were exchanged, compared to its average volume of 1,158,185. Endocyte, Inc. has a twelve month low of $1.17 and a twelve month high of $6.55.

Endocyte (NASDAQ:ECYT) last issued its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.20). Endocyte had a negative net margin of 82,235.72% and a negative return on equity of 38.91%. The company had revenue of $0.03 million for the quarter. During the same quarter last year, the firm earned ($0.21) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. equities research analysts expect that Endocyte, Inc. will post -1.24 earnings per share for the current fiscal year.

A number of equities research analysts recently commented on the stock. ValuEngine cut shares of Endocyte from a “hold” rating to a “sell” rating in a research report on Tuesday, November 14th. Zacks Investment Research upgraded shares of Endocyte from a “sell” rating to a “hold” rating in a research note on Thursday, November 9th. Wedbush upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating and upped their price target for the company from $2.00 to $7.00 in a research note on Tuesday, October 3rd. Finally, Cowen restated a “hold” rating on shares of Endocyte in a research note on Monday, October 2nd.

Several large investors have recently added to or reduced their stakes in ECYT. Bank of New York Mellon Corp increased its stake in shares of Endocyte by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after acquiring an additional 6,469 shares during the period. Renaissance Technologies LLC increased its stake in shares of Endocyte by 284.4% in the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 142,461 shares during the period. Spark Investment Management LLC acquired a new stake in shares of Endocyte in the second quarter worth $177,000. LMR Partners LLP acquired a new stake in shares of Endocyte in the second quarter worth $196,000. Finally, FMR LLC increased its stake in shares of Endocyte by 0.9% in the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after acquiring an additional 31,168 shares during the period. Hedge funds and other institutional investors own 17.68% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Christopher P. Leamon Sells 23,231 Shares of Endocyte, Inc. (NASDAQ:ECYT) Stock” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2017/12/13/endocyte-inc-ecyt-vp-sells-117084-24-in-stock.html.

Endocyte Company Profile

Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply